Screener
Denali Therapeutics Inc. DNLI Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accounts payable | 4,102 | (43) |
| Accruals and other current liabilities | (19,107) | (14,151) |
| Deferred research and development funding liability | (1,126) | 16,176 |
| Net cash used in operating activities | (228,206) | (206,766) |
| Investing activities | ||
| Purchases of marketable securities | (394,579) | (137,926) |
| Maturities and sales of marketable securities | 417,032 | 323,965 |
| Purchases of property and equipment | (3,271) | (9,356) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Denali Therapeutics Inc.'s operating cash flow?
- Denali Therapeutics Inc. (DNLI) reported operating cash flow of -$97M in Q2 2026.
- How has Denali Therapeutics Inc.'s operating cash flow changed year-over-year?
- Denali Therapeutics Inc.'s operating cash flow decreased by 28.8% year-over-year, from -$75.3M to -$97M.
- What is the long-term trend for Denali Therapeutics Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s operating cash flow has grown at a 18.2% compound annual growth rate (CAGR), from -$211.39M to -$412.6M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Denali Therapeutics Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude